Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia

Haematologica

Volumn 99, Issue 9, 2014, Pages 1456-1464

  Yun, Haiyang ^a   Damm, Frederik ^b   Yap, Damian ^c,d   Schwarzer, Adrian ^a   Chaturvedi, Anuhar ^a   Jyotsana, Nidhi ^a   Lübbert, Michael ^e   Bullinger, Lars ^f   Döhner, Konstanze ^f   Geffers, Robert ^g   Aparicio, Samuel ^c,d   Humphries, R Keith ^d,h   Ganser, Arnold ^a   Heuser, Michael ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD11B ANTIGEN; CORE BINDING FACTOR; FLT3 LIGAND; HEMOGLOBIN; HOMEODOMAIN PROTEIN; LACTATE DEHYDROGENASE; MEIS HOMEOBOX 1; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; RETINOIC ACID; RIBOSOME PROTEIN; SURFEIT LOCUS PROTEIN 1; SYNTAXIN; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE 3A; MESSENGER RNA; MLL5 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION ASSAY; CELL PROLIFERATION ASSAY; CHROMOSOME ABERRATION; COLONY FORMING CELL; CONTROLLED STUDY; DNA METHYLATION; DNA METHYLTRANSFERASE 3A GENE; DNA MICROARRAY; DRUG EFFICACY; DRUG MEGADOSE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MOUSE; MRNA EXPRESSION ASSAY; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; RETROVIRUS INFECTION; TRANSCRIPTION REGULATION; AGED; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MARROW CELLS; CELLS, CULTURED; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DNA-BINDING PROTEINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 84907376360     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.101386     Document Type: Article

References (40)

1. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program. 2008;1:1-11.
2. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12(9):599-612.
3. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-94.
4. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987-96.
5. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-7.
6. Emerling BM, Bonifas J, Kratz CP, Donovan S, Taylor BR, Green ED, et al. MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene. 2002;21(31):4849-54.
7. Madan V, Madan B, Brykczynska U, Zilbermann F, Hogeveen K, Dohner K, et al. Impaired function of primitive hematopoi-etic cells in mice lacking the Mixed-Lineage-Leukemia homolog MLL5. Blood. 2009;113(7):1444-54.
8. Sebastian S, Sreenivas P, Sambasivan R, Cheedipudi S, Kandalla P, Pavlath GK, et al. MLL5, a trithorax homolog, indirectly regulates H3K4 methylation, represses cyclin A2 expression, and promotes myogenic differentiation. Proc Natl Acad Sci USA. 2009;106(12):4719-24.
9. Cheng F, Liu J, Zhou SH, Wang XN, Chew JF, Deng LW. RNA interference against mixed lineage leukemia 5 resulted in cell cycle arrest. Int J Biochem Cell Biol. 2008;40(11):2472-81.
10. Deng LW, Chiu I, Strominger JL. MLL 5 protein forms intranuclear foci, and overex-pression inhibits cell cycle progression. Proc Natl Acad Sci USA. 2004;101(3):757-62.
11. Liu J, Wang XN, Cheng F, Liou YC, Deng LW. Phosphorylation of mixed lineage leukemia 5 by CDC2 affects its cellular distribution and is required for mitotic entry. J Biol Chem. 2010;285(27):20904-14.
12. Sambasivan R, Pavlath GK, Dhawan J. A gene-trap strategy identifies quiescence-induced genes in synchronized myoblasts. J Biosci. 2008;33(1):27-44.
13. Heuser M, Yap DB, Leung M, de Algara TR, Tafech A, McKinney S, et al. Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. Blood. 2009;113(7):1432-43.
14. Zhang Y, Wong J, Klinger M, Tran MT, Shannon KM, Killeen N. MLL5 contributes to hematopoietic stem cell fitness and homeostasis. Blood. 2009;113(7):1455-63.
15. Damm F, Oberacker T, Thol F, Surdziel E, Wagner K, Chaturvedi A, et al. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol. 2011;29(6):682-9.
16. Lubbert M, Ruter BH, Claus R, Schmoor C, Schmid M, Germing U, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97(3): 393-401.
17. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617-28.
18. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13-27.
19. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94(1): 131-4.
20. Calvo KR, Sykes DB, Pasillas M, Kamps MP. Hoxa9 immortalizes a granulocyte-macrophage colony-stimulating factor-dependent promyelocyte capable of biphe-notypic differentiation to neutrophils or macrophages, independent of enforced meis expression. Mol Cell Biol. 2000;20(9): 3274-85.
21. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010;5(2):e9001.
22. Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood. 2013;121(9):1633-43.
23. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21(3):430-46.
24. Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol. 2008;61(5):759-66.
25. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoi-etic malignancies. Blood. 2004;103(5): 1635-40.
26. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52-7.
27. Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T, et al. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4: 11) abnormality. Oncogene. 2001;20(7):874-8.
28. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998;17 (13):3714-25.
29. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet. 2005;37(8):853-62.
30. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA. 1997;94(2):569-74.
31. Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, Li Y, et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood. 2011;117(1):234-41.
32. Ali M, Rincon-Arano H, Zhao W, Rothbart SB, Tong Q, Parkhurst SM, et al. Molecular basis for chromatin binding and regulation of MLL5. Proc Natl Acad Sci USA. 2013;110 (28):11296-301.
33. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. Impaired hydroxylation of 5-methylcyto-sine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839-43.
34. Deplus R, Delatte B, Schwinn MK, Defrance M, Mendez J, Murphy N, et al. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J. 2013;32(5): 645-55.
35. Zhou P, Wang Z, Yuan X, Zhou C, Liu L, Wan X, et al. Mixed lineage leukemia 5 (MLL5) protein regulates cell cycle progression and E2F1-responsive gene expression via association with host cell factor-1 (HCF-1). J Biol Chem. 2013;288(24):17532-43.
36. Zouridis H, Deng N, Ivanova T, Zhu Y, Wong B, Huang D, et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med. 2012;4(156):156ra40.
37. Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012;120(12): 2466-74.
38. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, et al. Impact of TET2 mutations on response rate to azacitidine in myelodys-plastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147-52.
39. Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26(5): 1106-7.
40. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;19(1):138-52.